---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-095506"
form_type: "8-K"
ticker: "ESLA"
cik: "0001844417"
company_name: "Estrella Immunopharma, Inc."
filed_at: "2024-11-07T23:59:59+00:00"
generated_at: "2026-05-30T03:50:15.969987+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# Estrella Immunopharma enters employment agreement with CEO Cheng Liu; base salary $250,000

## Summary
- Base salary of $250,000 per year, plus annual cash bonus based on performance metrics set by Compensation Committee.
- Severance: 6 months base salary for termination without cause or resignation for good reason; 12 months plus equity acceleration if tied to change in control.
- Agreement includes non-disclosure and confidentiality covenants; effective November 1, 2024, at-will employment.
- CEO retains ability to hold outside directorships and positions, subject to Board review.

## SEC filing metadata
- accession: 0001213900-24-095506
- form_type: 8-K
- ticker: ESLA
- cik: 0001844417
- company_name: Estrella Immunopharma, Inc.
- filed_at: 2024-11-07T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1844417/000121390024095506/0001213900-24-095506-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1844417/000121390024095506/ea0220428-8k_estrella.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-095506
- JSON: https://secwatch.observer/filing/0001213900-24-095506.json
- Plain text: https://secwatch.observer/filing/0001213900-24-095506.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.